Last reviewed · How we verify
NCT06314126: ENDO-DCI
Evaluation of D-Chiro-Inositol Treatment in Women With Endometriosis
NA trial testing D-Chiro-Inositol in Endometriosis in 64 participants. Completed in 15 March 2025.
15 February 2025
Quick facts
| Lead sponsor | University of Palermo |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 15 April 2024 |
| Primary completion | 15 February 2025 |
| Estimated completion | 15 March 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- D-Chiro-Inositol — full drug profile →
- Placebo
Conditions studied
- Endometriosis — all drugs for Endometriosis →
Sponsor
University of Palermo
Who can join
Adults 18 to 40, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To date, the treatment for endometriosis is represented by the surgical removal of the lesions. Nonetheless, in the years following surgery, the lesions can recur, often due to excessive estrogen production. To balance estrogen, progestin- or estrogen-progestin-based medications are generally prescribed. On the other hand, progestins and estrogen-progestins act as contraceptives, preventing the onset of a pregnancy. At the same time, these can have side effects that can affect up to 30% of patients. For these and other reasons, some women refuse therapy with progestins or estrogen-progestins, preferring to resort to no treatment. Considering the need to research effective molecules in the prevention of relapses that can maintain fertility and avoid unwanted effects, the research focuses on natural molecules, well tolerated by the body. D-Chiro-Inositol (DCI) is a polyol normally present in human cell membranes, where, from a metabolic point of view, it acts as a second messenger of insulin, while from a hormonal point of view, it exerts an on the biosynthesis of androgens. This effect on steroidogenesis can be attributed to more than one mechanism. In the ovary, DCI stimulates direct testosterone production. Furthermore, it stimulates the accumulation of testosterone by reducing the activity of the aromatase enzyme, responsible for the conversion of androgens into estrogens. Considering the responsiveness of endometriosis to estrogens, and that these constitute a risk factor for recurrences following surgical removal, the use of DCI could be interesting from a clinical point of view. The study plans to verify whether D-Chiro-Inositol dietary supplementation can be effective in reducing systemic estrogen levels in women with endometriosis, thus also reducing the risk of relapses and associated symptoms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06314126
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometriosis
Currently open trials in the same condition.
- NCT06559852 — The Impact of Yoga on Endometriosis-Related Pain · NA · recruiting
- NCT07393295 — Efficacy and Tolerability of TENS in Endometriosis-related Pain · NA · recruiting
- NCT07134023 — Educational Program for the Multidisciplinary Support of Patients With Endometriosis · NA · recruiting
- NCT07240883 — ENDO1000 - A UK-wide Endometriosis Research Project · recruiting
- NCT06974773 — Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups · NA · recruiting
Other University of Palermo trials
Trials by the same sponsor.
- NCT03017716 — Inflammatory Back Pain and Gluten Free Diet · NA · not yet recruiting
- NCT07364149 — Acute Effects of Structured Exercise and Static Stretching on Vascular Function, Neuromuscular Performance, and Metaboli · NA · recruiting
- NCT06206616 — Liver Steatosis in Pediatric CD Patients · not yet recruiting
- NCT07433543 — Foam Rolling, Blood Pressure and Range of Motion · NA · completed
- NCT07213011 — Effects of Static Stretching and Self-myofascial Release on Local and Remote Range of Motion · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06314126 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Palermo
- Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06314126.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing